3060 Pegasus Park Drive
Building 6
Dallas, TX 75247
United States
310 618 6994
https://www.fortebiorx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 9
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Dr. Paul A. Wagner Ph.D. | CEO, President & Chairman | 960.23k | 無 | 1970 |
Mr. Antony A. Riley CPA | Chief Financial Officer | 568.48k | 無 | 1967 |
Dr. Barbara K. Finck M.D. | Chief Medical Clinician & Director | 45k | 無 | 1947 |
Mr. Christopher Roenfeldt | Chief Operating Officer | 無 | 無 | 無 |
Mr. Steven Ruhl | Chief Technical Officer | 無 | 無 | 1957 |
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
截至 無 止,Forte Biosciences, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。